Details for Patent: 9,642,911
✉ Email this page to a colleague
Which drugs does patent 9,642,911 protect, and when does it expire?
Patent 9,642,911 protects VALCYTE and is included in one NDA.
This patent has thirty-six patent family members in thirty-one countries.
Summary for Patent: 9,642,911
Title: | Pharmaceutical dosage forms comprising valganciclovir hydrochloride |
Abstract: | The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms. |
Inventor(s): | Bachynsky; Maria Oksana (Nutley, NJ), Infeld; Martin Howard (Upper Montclair, NJ), Shah; Navnit Hargovindas (Clifton, NJ) |
Assignee: | Hoffmann-La Roche Inc. (Little Falls, NJ) |
Application Number: | 14/529,839 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,642,911 |
Patent Claim Types: see list of patent claims | Composition; Dosage form; |
Drugs Protected by US Patent 9,642,911
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cheplapharm | VALCYTE | valganciclovir hydrochloride | FOR SOLUTION;ORAL | 022257-001 | Aug 28, 2009 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,642,911
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 065541 | ⤷ Try a Trial | |||
Australia | 2007332640 | ⤷ Try a Trial | |||
Brazil | PI0720118 | ⤷ Try a Trial | |||
Canada | 2671470 | ⤷ Try a Trial | |||
Chile | 2007003564 | ⤷ Try a Trial | |||
China | 101541310 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |